Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Big Stock Moves on NLRP3 Competitive Landscape News; Positive Read-throughs for Neumora Therapeutics (NMRA) - Mizuho
January 7, 2026 1:20 PM ESTMizuho analyst Graig Suvannavejh reiterated an Outperform rating and $6.00 price target on Neumora Therapeutics (NASDAQ: NMRA)
The analyst comets "NMRA shares are +25-30 intraday (vs. +3% XBI) and +50% (vs. +5% XBI) over the past two trading sessions, following we believe recent media... More
